Compare Davita Inc (DVA) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Oracle Corporation — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Oracle Corporation trades at $129.15 (market cap $368.53B). The key difference: Oracle Corporation is far larger — about 24.7× Davita Inc's market cap, and Oracle Corporation pays a 1.56% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | ORCL | |
|---|---|---|
Market Cap | $14.92B | $368.53B |
Sector | Health | Technology |
52-Week High | $235.71 | $328.33 |
52-Week Low | $103.87 | $127.96 |
Enterprise Value | $27.47B | $497.78B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Oracle Corporation (ORCL) is trading at $127.96, down 9.04% today, reflecting recent market volatility. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $2.11 vs. $1.96 expected) and robust profitability (net margin of 25.37%). Technical indicators are bearish with support at $124, while analyst consensus remains bullish with a $259 price target. Recent news highlights Oracle's AI infrastructure expansion and partnership with OpenAI.
Outlook: Oracle's AI-driven growth and solid financials support long-term upside, but near-term risks include high debt levels and competitive pressures. The stock offers value for investors seeking exposure to enterprise software and cloud infrastructure, with earnings on June 10, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
